Table 2 Univariable and multivariable analyses of factors associated with disease free survival in the full cohort, women and men

Age

Continuous

1.01 (0.97-1.05)

1.00 (0.95-1.05)

1.01 (0.95-1.07)

0.98 (0.94-1.02)

1.00 (0.94-1.06)

1.00 (0.92-1.09)

Sex

Women

1.00

-

-

1.00

-

-

Men

1.51 (0.85-2.70)

-

-

1.06 (0.52-2.15)

-

-

Histological subtype

LMM + SSM

1.00

1.00

1.00

1.00

1.00

1.00

NMM

5.63 (3.15-10.08)

6.36 (2.67-15.12)

5.39 (2.41-12.09)

1.21 (0.55-2.63)

1.47 (0.48-4.54)

1.49 (0.46-4.82)

Breslow thickness

<=1 mm

1.00

1.00

1.00

1.00

1.00

1.00

> 1 mm

8.44 (4.27-16.68)

12.17 (4.07-36.34)

6.12 (2.14-14.73

0.61 (0.10-3.70)

0.17 (0.01-2.95)

1.45 (0.15-14.22)

Clark level

II-III

1.00

1.00

1.00

1.00

1.00

1.00

IV-V

3.75 (2.11-6.69)

6.28 (2.65-14.89)

2.37 (1.07-5.22)

0.52 (0.26-1.03)

1.04 (0.32-3.43)

0.36 (0.12-1.07)

Ulceration

No

1.00

1.00

1.00

1.00

1.00

1.00

Yes

5.82 (3.13-10.80)

5.90 (2.41-14.42)

7.21 (2.97-17.48)

1.56 (0.65-3.76)

0.70 (0.23-2.12)

5.46 (1.70-17.53)

Clinical stage

1

1.00

1.00

1.00

1.00

1.00

1.00

2-4

15.02 (16.39-35.30)

25.41 (5.81-111.08)

11.76 (3.86-35.87)

5.56 (3.02-24.28)

6.88 (1.64-28.89)

6.39 (1.56-26.25)

Vascular invasion

No

1.00

1.00

1.00

1.00

1.00

1.00

Yes

9.25 (3.56-17.79)

20.48 (5.47-76.65)

6.87 (2.96-15.97)

3.44 (1.63-7.25)

4.79 (1.21-19.01)

11.15 (3.42-36.38)

Mitotic count

0/mm²

1.00

1.00

1.00

1.00

1.00

1.00

> = 1/mm²

7.95 (3.56-17.80)

27.24 (3.65-203.10)

4.83 (1.92-12.13)

3.28 (1.11-9.73)

6.87 (0.77-61.05)

2.21 (0.53-9.13)

Lymphocytic infiltrate

None-mild

1.00

1.00

1.00

1.00

1.00

1.00

Moderate-brisk

0.43 (0.24-0.78)

0.45 (1.19-1.08)

0.43 (0.19-0.94)

0.73 (0.37-1.44)

0.87 (0.31-2.43)

0.69 (0.25-1.90)

Ki67 expression

0-25%

1.00

1.00

1.00

1.00

1.00

1.00

>25%

2.46 (1.33-4.56)

1.67 (0.67-4.15)

4.06 (1.74-9.48)

1.74 (0.85-3.54)

0.96 (0.24-3.78)

6.14 (1.76-21.39)